News

Ascendis Seeks FDA Approval of TransCon PTH for Adults

Ascendis Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its treatment candidate TransCon PTH for adults with hypoparathyroidism, the company announced. “Our data support that TransCon PTH, if approved, could become the first-in-class therapy to address the underlying cause of…

Chronic Hypoparathryroidism Tied to Kidney Complications: Study

Patients with long-lasting hypoparathyroidism in Sweden are over three times more likely than healthy individuals to develop kidney complications such as chronic kidney disease and kidney stones, and this may translate into more frequent hospital admissions, a study found. The study, “Kidney Complications and Hospitalization in Patients with…

Low Calcium Found to Affect Certain Cognitive Functions Post-surgery

Patients with chronic hypoparathyroidism following surgery for thyroid cancer do not have overall significant cognitive impairments, but those with lower blood calcium levels showed some disruptions in cognitive function, according to a study. Specifically, patients with lower calcium levels exhibited impairments in visuo-spatial attention, semantic memory (memory of general…

Natpara May Help in Maintaining Heart Health, Trial Data Show

Adults with hypoparathyroidism given long-term treatment with Natpara are less likely to experience heart-related health problems, according to an analysis of data from three clinical trials. Natpara “may confer cardiovascular benefits to patients with chronic hypoparathyroidism, and further research is warranted to understand the relationship better in a real-world setting,” the researchers…

Hormone Replacement Therapy MBX 2109 Named FDA Orphan Drug

MBX 2109, an experimental hormone replacement therapy that MBX Biosciences is developing for hypoparathyroidism, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA). The FDA awards this designation to therapies intended to treat rare diseases, defined as those that affect less than 200,000 people…